Aulos Bioscience is an immuno-oncology company that aims to revolutionize cancer patient care through its computationally designed IL-2 therapeutics. The company's flagship clinical candidate, AU-007, has been engineered to leverage a patient's own IL-2 to induce tumor killing while minimizing associated toxicities. Founded in 2020 by Biolojic Design and ATP, Aulos Bioscience secured a substantial $40M Series A investment from Apple Tree Partners. The startup, based in the United States, combines world-class machine learning with a deep understanding of the immune system and is poised to make significant contributions to biotechnology and healthcare. Aulos Bio's focus on leveraging the power of the immune system to combat cancer positions it as a promising player in the evolving immuno-oncology landscape. With its groundbreaking approach and strong financial backing, Aulos Bioscience presents an exciting opportunity for potential investors and stakeholders in the cancer care industry.
Aulos Bioscience
We’re revolutionizing #cancercare through #IL2 therapeutics designed to direct the #immunesystem to destroy cancers.
Larkspur, United States
15 employees
Series A
Total: $60.00M
Biotechnology, Health Care +2
General Information
Larkspur, United States
BounceWatch is an independent company data service, not affiliated with Aulos Bioscience. To contact Aulos Bioscience, visit aulosbio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Aulos Bioscience compare?
A PDF of Aulos Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Aulos Bioscience soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.
Aulos Bioscience will be presenting new imneskibart data at the SITC annual meeting, detailing results from their ongoing Phase 1/2 study in CPI-refractory adenocarcinoma NSCLC and doublet CPI-refr…
About Aulos Bioscience
Business keywords: immuno-oncology, IL-2 therapeutics, cancer care, immune system, clinical candidate, tumor killing, immunosuppression, toxicity, solid tumors, antibody development, cancer immunotherapies, Biolojic Design, ATP funding
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | $20.00M | 1 |
|
01 Aug 2023 |
| Series A | $40.00M | 1 |
|
01 Jan 2021 |
Aulos Bioscience Alternatives & Competitors
View All Alternatives
SPEARHEADING IMMUNOTHERAPIES
Novel Target for Solid Tumors
Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of...
Pyxis Oncology
FAQ About Aulos Bioscience
Source: BounceWatch company record for Aulos Bioscience, https://bouncewatch.com/company/aulos-bioscience, updated 1 July 2026. When citing, please name BounceWatch and link this page.
